In this cohort, 5.4% of asymptomatic BRCA mutation carriers had occult carcinomas in risk-reducing surgery specimens.
Patients with STIC had a higher incidence of subsequent serous cancer than those with benign adnexa.
The optimal postoperative management of patients with occult STIC lesions is unknown.